GT Biopharma Inc (GTBP)

[oxis007]

There are currently 400 million outstanding shares.

Assume they do a 100-1 reverse split in order to uplist. Now they will have 4 million shares outstanding however, now you'll only have a hundredth of what you had prior to the split. Example, I'll give you my current investment in Oxis. I currently have 130,000 shares at a price of $0.074 per share. After the split I'll now have 1,300 shares at a price of $7.4 per share. Assuming after the up list they sell an additional 56 million shares. They will now have 60 million outstanding (4 million from the reverse split plus 56 million from the ipo). As long as the stock price stays at or above $7.40 with a market cap of 444 million. I'm okay. Anything below that, I'm losing money.

So again my answer is I think there will be a total of 60 million shares outstanding after the reverse split.

The reason they won't have anywhere near 750 million after the split, is because then they remain a penny stock. (In order for them to not be a penny stock with 750 million shares outstanding, they'd need a price per share of $5.00 which would assume a 3.75 billion market cap.) Which until they at the very least have a phase three trial ongoing or NDA is highly unlikely.

So again my answer is I think there will be a total of 60 million shares outstanding after the reverse split.
Worst case scenario, 100 million, but remember this is after the reverse split.


Kite Pharma: 57 million source NASDAQ

Juno Therapeutics : 106 million outstanding source NASDAQ

Bluebird Bio: 41 million outstanding source NASDAQ